ASPIRE interferon beta-1b in combination with azathioprine for secondary progressive multiple sclerosis: a 2-year, double blind, randomizesed, multicentre, pilot study. EDSS; MSQOL54 and safety data
E. Montanari(University of Milan), Luca Durelli(University of Turin), A. Ghezzi(Azienda Ospedaliera Sant’Antonio Abate di Gallarate), Elio Scarpini(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), E. Merelli(University of Pisa), Ilaria Pesci, L. Manneschi, Paola Cavalla, L. Motti(Santa Maria Nuova Hospital), M. R. Tola(Vita-Salute San Raffaele University), Leandro Provinciali(Ospedali Riuniti di Ancona), D. Caputo, Maria Giovanna Marrosu(University of Cagliari)
Unknown
January 1, 2004
Cited by 0
Related Papers
Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study
|The Lancet|2001|1.1k
Multiple Sclerosis Severity Score
|Neurology|2005|959
Genome-wide Analyses Identify KIF5A as a Novel ALS Gene
|Neuron|2018|724
Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN)
|The Lancet|2002|552
Evidence of early cortical atrophy in MS
|Neurology|2003|485